Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), relating to the proposed merger with Johnson & Johnson. Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies for a payment of $132.00 per share in cash.